Lifecore pullback creates attractive entry point, says Craig-Hallum

President Trump attended a National Republican Congressional Committee event and during his speech commented that he will announce large tariffs on drug imports “very shortly,” a clear sign that the pharma industry will not be spared of tariffs, Craig-Hallum tells investors in a research note. The firm believes Lifecore (LFCR) is well-positioned to benefit from the pending onshoring wave and reiterates a Buy rating on the shares. The firm says the recent pullback in the shares creates an attractive entry point.